Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA)

HIV Medicine

Volumn 11, Issue 8, 2010, Pages 530-534

  Di Vincenzo, P ^a   Rusconi, S ^a   Adorni, F ^b   Vitiello, P ^a   Maggiolo, F ^c   Francisci, D ^d   Di Biagio, A ^e   Monno, L ^f   Antinori, A ^g   Boeri, E ^h   Punzi, G ^f   Perno, C F ^g   Callegaro, A ^c   Bruzzone, B ^e   Zazzi, M ⁱ  

^a UNIVERSITY OF MILAN   (Italy)

^b CNR   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d Perugia Hospital   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f UNIVERSITY OF BARI   (Italy)

^g NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^h HSR TIGET   (Italy)

ⁱ UNIVERSITY OF SIENA   (Italy)

Author keywords

ARCA; Drug resistance; Genotype; HIV 1; TMC125

Indexed keywords

EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; NEVIRAPINE; PROTEINASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS MUTATION;

ADULT; ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; ITALY; MALE; MULTIVARIATE ANALYSIS; MUTATION; PREVALENCE; PYRIDAZINES; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 77955264812     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00819.x     Document Type: Article

References (17)

1. Zaccarelli M, Tozzi V, Lorenzini P. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 2005, 19:1081-1089.
2. Perno C-F, Moyle G, Tsoukas C, Ratanasuwan W, Gatell J, Schechter M. Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs. J Med Virol 2008, 80:565-576.
3. Andries K, Azijn H, Thielemans T. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004, 48:4680-4686.
4. Vingerhoets J, Azijn H, Fransen E. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005, 79:12773-12782.
5. Madruga JV, Cahn P, Grinsztejn B. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007, 370:29-38.
6. Lazzarin A, Campbell T, Clotet B. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007, 370:39-48.
7. Vingerhoets J, Buelens A, Peeters M. Impact of baseline NNRTI mutations on the virological response to TMC125 in the phase III clinical trials DUET-1 and DUET-2. Antivir Ther 2007, 12:S34.
8. Vingerhoets J, Clotet B, Peeters M. Impact of baseline NNRTI mutations on the virological response to TMC125 (etravirine, ETR) in the DUET-2 phase III clinical trials. 11th European AIDS Conference. Madrid, Spain, 24-27 October, 2007 [Abstract P7.3/05]
9. Tambuyzer L, Vingerhoets J, Azijn H. Development of a list of mutations associated with NNRTI resistance for use in clinical research. 5th European HIV Drug Resistance Workshop. Cascais, Portugal, 28-30 March, 2007 [Abstract 67]
10. Tambuyzer L, Vingerhoets J, Azijn H, Daems B, Picchio G, de Béthune MP. Emerging mutations in patients with virological failure on TMC125 in the DUET-1 and DUET-2 clinical trials. 6th European HIV Drug Resistance Workshop. Budapest, Hungary, 26-28 March, 2008 [Abstract 47]
11. Picchio G, Vingerhoets J, Staes M. Prevalence of TMC125 resistance-associated mutations in a large panel of clinical isolates. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2-6 February, 2008 [Abstract 866]
12. Poveda E, Garrido C, de Mendoza C. Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2007, 60:1409-1410.
13. Llibre JM, Santos JR, Puig T. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. J Antimicrob Chemother 2008, 62:909-913.
14. van den Berg-Wolf M, Huppler Hullsiek K, Peng G. Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. HIV Clin Trials 2008, 9:324-336.
15. MacArthur RD, Huppler Hullsiek K, Peng G. Failing therapy with efavirenz results in significantly fewer mutations limiting to etravirine than failing therapy with nevirapine: on-treatment analyses from the CPCRA FIRST Study. Antivir Ther 2008, 13((Suppl 3)):A141.
16. Tambuyzer L, Vingerhoets J, Azijn H, Hoogstoel A, Nijs S, Picchio G. Comparison of two etravirine weighted genotypic scores with phenotypic susceptibility and virological response data. 7th European HIV Drug Resistance Workshop, Stockholm, Sweden, 25-27 March, 2009 [Abstract 114]
17. Johnson V, Brun-Vézinet F, Clotet B. Update of the drug resistance mutations in HIV-1: December 2008. Top HIV Med 2008, 16:138-145.